Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3 Meeting Abstract
| Authors: | Abdelrahim, M.; Khan, G.; Hatoum, H.; Zervoudakis, A.; Dayyani, F.; Zhang, L.; Li, J.; Maxwell, F.; O'Reilly, E. M.; Wainberg, Z. A.; Peters, M. L. B. |
| Abstract Title: | Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3 |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.717 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 717 -- Source: CINAHL Plus with Full Text |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
780O'Reilly -
31Zervoudakis
Related MSK Work